and pathophysiological conditions, 10 including angiogenesis in cancer and chronic inflammatory disease progression. 11 Prostaglandin E 2 (PGE 2 ) is a major product of cyclooxygenase 2 catalysis in inflamed tissue and is implicated in both physiological and pathological angiogenesis.
12-14 PGE 2 exerts its diverse biological functions through 4 different G proteincoupled receptors, that is, EP1-4. The EP1 receptor couples to Gq and mediates intracellular calcium release. The EP2 and EP4 receptors couple to Gs and activate protein kinase A (PKA) by increasing the concentration of intracellular cAMP. In contrast, the PGE 2 receptor subtype 3 (EP3) couples to Gi to suppress PKA activity. 15 PGE 2 displays multiple proangiogenic properties through promoting VEGF, basic fibroblast growth factor, and C-X-C chemokine motif 1 production [16] [17] [18] or directly mediating EC migration and survival. 13, 19 Although decreased tumorassociated angiogenesis has been reported in all the EP knockout animals, 12, [20] [21] [22] [23] only EP3 agonists have been shown to markedly enhance angiogenesis in vivo among various EP-specific agonists tested. 23 Similarly, only EP3 antagonists have been shown to significantly block cathelicidin-induced angiogenesis. 24 In a mouse model of diabetes mellitus, only the EP3 receptor was found to be downregulated in sponge granulation tissues, and a selective agonist of EP3 receptor effectively reversed the suppressed angiogenesis. 25 Despite increased evidences indicate that EP3 has an important role in angiogenesis, the specific mechanisms through which EP3 mediates angiogenesis, particularly related to vascular sprouting during development, remain to be elucidated.
In present study, we demonstrated that the EP3 receptor facilitated angiogenesis by modulating EC sprouting during zebra fish development and mouse retina formation through suppression of Dll4 expression and Notch activation. Activation of the EP3 receptor suppressed PKA-mediated β-catenin phosphorylation, attenuated the nuclear translocation of β-catenin, and downregulated the β-catenin-target gene Dll4. Thus, our findings supported that the PGE 2 /EP3 axis mediated sprouting angiogenesis through a PKA/β-catenin/Dll4/Notch signaling pathway.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Deletion of EP3 Receptor Suppresses Angiogenesis During Zebra Fish Embryonic Development
First, we examined the expression patterns of EP3 during zebra fish embryonic development using whole-mount in situ hybridization. As shown in Figure 1A , EP3 expression was detected in blastomeres from 3.5 to 6 hours post fertilization (hpf). From 18 to 24 hpf, EP3 was prominently expressed in the axial vasculature and head region ( Figure 1A ), particularly in the dorsal aorta and posterior cardinal vein. We further collected zebra fish ECs from Tg(fli1:EGFP) y1 embryos by flow cytometry at 24 hpf ( Figure 1B) , and reverse transcription polymerase chain reaction showed EP3 was expressed in ECs ( Figure 1C ). We then examined vascular formation in Tg(fli1:EGFP) y1 embryos by knocking down the EP3 receptor. As shown in Figure 1D and 1E, knockdown of EP3 impaired intersegmental vessel sprouting and decreased the number of connected dorsal longitudinal antastomotic vessel segments at 26 and 48 hpf. Similar phenomena were observed in zebra fish treated with the EP3-specific antagonist L-798106 ( Figure 1F and 1G) . To further confirm the vascular defects caused by EP3 loss, we examined intersegmental vessel formation in Tg(fli1:nEGFP) y7 embryos in which EGFP (enhanced green fluorescent protein) expression was limited in the nucleus of ECs and found that knockdown or pharmacological inhibition of the EP3 receptor decreased the number of ECs migrating toward the dorsal side in sprouting intersegmental vessels at 26 and 48 hpf ( Figure 1H through 1K ).
Endothelial-Specific Deletion of EP3 Receptor Compromises Neovascularization During Development of the Mouse Retina
We then evaluated the effects of EP3 deletion on neovascularization in postnatal retinas in mice. EP3-floxed mice (EP3 f/f ) were crossed with Tie2-Cre transgenic mice to obtain an EC-specific EP3 deletion line 26 (EP3 f/f Tie2 Cre ). EP3 deletion in ECs did not influence serum interleukin-6, tumor necrosis factor-α, interleukin-4, interleukin-10, VEGF, and epidermal growth factor levels in mice (data not shown). Interestingly, compared with EP3 f/f littermates, EP3 f/f Tie2 Cre mice had significantly reduced retinal vessel outgrowth with delayed extension toward the periphery at postnatal day 2 (Figure 2A and 2B ). In addition, vascular branches and density were markedly reduced at postnatal day 5 in EP3 f/f Tie2 Cre mice ( Figure 2C and 2D). One hallmark of angiogenesis is the emergence of filopodia extending from endothelial tip cells, indicating that ECs have acquired an autonomous patterning ability. 27, 28 Strikingly, tip cells and sprouting filopodias during retinal neovascular formation were reduced by nearly 50% at postnatal day 5 in EP3 f/f Tie2 cre mice as compared with those in control mice ( Figure 2E through 2G) . On the contrary, overexpression of EP3α significantly increased human umbilical vein EC tube formation in 2-dimensional Matrigel gels ( Figure IA through 1D in the online-only Data Supplement).
Deletion of EP3 Receptor Suppresses Angiogenesis in Response to Ischemia in Mice
In addition, in a murine model of hindlimb ischemia, we also found that EP3 deletion led to attenuated vascular formation and ultimately decreased blood reperfusion in ischemic limbs of EP3 
Augmented Dll4/Notch Activation Leads to Impaired Sprouting Angiogenesis in Postnatal Retinas in EP3-Deficient Mice
Dll4/Notch signaling suppresses blood vessel sprouting by modulation of tip cell formation and behavior. 6, 29, 30 Indeed, specific knockdown or pharmacological inhibition of the EP3 receptor upregulated Dll4 expression in the vasculature during zebra fish embryo development ( Figure 3A ). Knockdown of Dll4 by morpholino injection dramatically restored the reduced dorsal longitudinal antastomotic vessel structures in EP3-deficient Tg(fli1:EGFP) y zebra fish ( Figure 3B ). Likewise, along with Dll4, the expression of several of Notch target genes (ie, Hey1 and Hes1) 30 was also significantly induced in postnatal retinas from EP3 f/f Tie2 cre mice ( Figure 3C ). Again, suppression of Notch signaling using the γ-secretase inhibitor N-[N- (3,5- 
difluorophenacetyl-l-alanyl)]-S-phenylglycine t-butylester rescued the impaired vascular formation in retinas of EP3
f/f Tie2 cre mice ( Figure 3D through 3F) . Therefore, these results demonstrated that EP3 activation could promote angiogenesis by inhibiting Dll4/Notch signaling.
EP3 Deficiency Does Not Influence Oxidative Stress in Retinas in Mice
Although reactive oxygen species are proved to promote angiogenesis through VEGF-dependent and -independent pathway, 31, 32 we failed to detect any significant differences in basal levels of H 2 O 2 , expression of NADPH oxidases (NOX1, 2, 3, and 4), and oxidative stress-induced factors, such as hypoxiainducible factors 1α, nuclear factor (erythroid-derived 2)-like 2, and heme oxygenase 1 in retinas between EP3 f/f and EP3 f/f Tie2 cre mice ( Figure IVA through IVC in the online-only Data Supplement). In addition, reactive nitrogen species, such as nitric oxide (NO), generated by endothelial NO synthase, have been proved to promote angiogenesis through stimulating both endothelial proliferation and migration. 33, 34 And caveolin negatively impacts endothelial NO synthase activity through direct interaction with endothelial NO synthase. 35, 36 Thus, we detected levels of caveolin-1 mRNA expression in mouse retinas, but found no significant difference between 
EP3 Deficiency Enhances the Transcriptional Activity of β-Catenin in ECs
Many factors are involved in regulating Dll4 expression during angiogenesis, including VEGF, 37 
Tie2
Cre pups ( Figure 4A ; Figure IVD in the online-only Data Supplement). Interestingly, the expression of the β-catenin target gene encoding cyclin D1 was markedly upregulated in the retinas of EP3 f/f Tie2 Cre mice ( Figure 4A ), indicating that β-catenin-mediated Wnt signaling maybe activated, despite the lack of change in β-catenin protein expression in EP3 −/− ECs ( Figure 4B ). Nuclear mobilization of β-catenin is critical for transcriptional activity. 45 Next, we analyzed the subcellular localization of β-catenin in ECs. The results showed that more β-catenin protein was distributed in the nucleus of EP3 −/− ECs than that of wild-type (WT) ECs ( Figure 4C ). Knockdown of β-catenin abolished the induction of Dll4 expression in the vasculature of EP3 morpholinotreated zebra fishes ( Figure 4D ) and EP3 −/− ECs ( Figure 4E ). Moreover, spheroid capillary sprouting assays showed that deletion of the EP3 receptor significantly decreased sprout numbers and shortened the sprout lengths of cultured ECs in vitro, while β-catenin silencing successfully rescued the sprouting defects 
cre newborn pups ( Figure 4I through 4K) . These results indicated that EP3 deficiency activated the Dll4/Notch pathway by increasing β-catenin activity in ECs during angiogenesis.
EP3 Deficiency Enhances β-Catenin Activity by PKA Activation in ECs
Previous studies have implied that PKA can directly phosphorylate β-catenin at Ser675 to promote its nuclear translocation and transcriptional activity. 46, 47 Given that EP3 couples to Gαi to inhibit adenylyl cyclase and downstream PKA activation, 48 we speculated that activation of the EP3 receptor may increase β-catenin activity by suppression of PKA-mediated phosphorylation of β-catenin at Ser675. To test this hypothesis, we first evaluated PKA activation in EP3 −/− ECs. Compared with that in WT ECs, PKA activity was significantly increased in EP3 −/− ECs ( Figure 5A and 5B), as in EP3 −/− vascular smooth muscle cells described previously. 49 We also found that the Ser675 residue of β-catenin was conserved in organisms from zebra fish to humans ( Figure 5C ). Western blot analysis showed that β-catenin phosphorylation at Ser675 was significantly increased in EP3 −/− ECs ( Figure 5D ), consistent with the observed enhancement of PKA activity. Interestingly, Ser675Ala mutation (S675A) attenuated S675 phosphorylation of β-catenin and abolished the increased Dll4 gene expression in L798106-treated ECs ( Figure VIA and VIB in the online-only Data Supplement). Moreover, the PKA kinase inhibitor H-89 abrogated the EP3 deficiencymediated increase in β-catenin phosphorylation at Ser675 ( Figure 5E ) and reduced the nuclear accumulation of β-catenin in EP3 −/− ECs ( Figure 5F ). Thus, these results suggested that EP3 deletion reduced β-catenin activity in a PKA-dependent manner. Inhibition of PKA suppressed the induction of Dll4 expression ( Figure 5G ) and rescued the intersegmental vessel defects in EP3 morpholino zebra fish ( Figure 5H) . Consistent with the results in zebra fish embryos, H89 ( Figure VIIA and VIIB in the online-only Data Supplement) abolished the increased Dll4 expression in EP3 −/− ECs ( Figure 5I ). Similar results were observed by using PKA regulatory and catalytic subunit dissociation blocker Rp-cAMPS (Rp-adenosine 3′,5′-cyclic monophosphorothioate; Figure VIIC 
Discussion
The PGE 2 /EP3 axis has been implicated in angiogenesis in many pathological conditions; however, the underlying molecular mechanisms remain exclusive. Here, we found that disruption of the EP3 receptor impaired vessel sprouting during angiogenesis and that β-catenin-mediated Dll4 expression was enhanced in EP3-deficient ECs. Moreover, we demonstrated that EP3 knockdown enhanced the nuclear localization of β-catenin by increasing PKA-mediated Ser675 phosphorylation in ECs. Therefore, activation of the EP3 receptor promoted angiogenesis through inhibition of PKA/β-catenin/ Notch signaling.
Sprouting and the induction of tip cells are early steps in angiogenesis. Tip cells use dynamic filopodia to sense guidance cues in their surroundings, enabling directional vessel growth. 50 Previous studies have demonstrated that inhibition of EP3 strongly attenuates capillary tube formation by ECs on Matrigel in vitro, 24 and tumor-bearing EP3 knockout mice display significantly decreased microvascular density in tumors, 23 indicating that EP3 plays a role in the determination of the sprouting pattern of ECs. Notably, EP3 is wildly expressed in human ocular tissues, including corneal, ciliary, conjunctiva, and retina, 51, 52 and plays an important role in regulation the of ocular surface inflammation in human. 53, 54 Indeed, we observed a significant decrease in the number of tip cells and a marked reduction in vessel outgrowth and branching in EP3 knockdown zebra fish embryos and mouse retinas. Dll4/Notch signaling is thought to act as a negative regulator of endothelial tip cell selection and vessel branching. 37, 55 Blockage of Dll4/Notch signaling leads to excessive tip cell formation and a dramatically increased vascular density, while activation of Notch signaling results in decreased vessel density. 6, 7, 30 In this study, we found that Dll4 expression was upregulated in EP3-deficient ECs and that inhibition of Dll4/Notch signaling effectively rescued the defective angiogenesis in EP3-deficient zebra fish embryos and mouse retinas. Thus, the proangiogenic effects of the EP3 receptor were facilitated by enhanced tip cell selection through inhibition of the Dll4/Notch signaling pathway.
The dynamics of Dll4 expression in ECs and tip cell formation during angiogenic sprouting are also regulated by VEGF.
6,56 However, we failed to detect a significant difference in VEGF expression in ECs between EP3-deficient and WT mice, indicating that endothelial upregulation of Dll4 was independent of the VEGF pathway. Evidence has shown that Wnt/β-catenin signaling, which is mainly regulated by posttranslational stabilization of β-catenin, and its translocation to the nucleus, where it interacts with cotranscription factors of the T cell factor or lymphoid enhancer factor family to drive target-gene expression, is involved in the regulation of angiogenesis and endothelial Dll4 expression. 57, 58 Sustained activation of β-catenin transcriptional activity causes vascular malformations at early embryonic developmental stages in mice. 44 Interestingly, we found augmented nuclear accumulation of β-catenin protein in EP3-deficient ECs and subsequent upregulation of its target genes, including Dll4. Pharmacological inhibition and genetic knockdown of β-catenin attenuated Dll4 induction in EP3-deficient ECs and rescued the decreased sprouting angiogenesis. Thus, EP3-mediated sprouting angiogenesis is dependent on β-catenin/Dll4 signaling. Consistent with our observations, activation of endothelial Wnt/β-catenin signaling leads to reduced vascular density and diminished tumor growth in murine glioma models, 59 and this reduced vascular formation caused by β-catenin activation is also dependent on Dll4. 44, 59 The cytoplasm-to-nucleus translocation of β-catenin is fine-tuned by numerous regulatory factors through modulation of a variety of different phosphorylation sites. 45 In quiescent cells, phosphorylation of Ser45 by casein kinase 1 and Ser33/Ser37/Thr41 by glycogen synthase kinase-3β leads to its ubiquitination and degradation, while inhibition of glycogen synthase kinase-3β through Wnt signaling results in enhanced stabilization and nuclear translocation by suppression of β-catenin phosphorylation. 60 In addition, PKA prevents β-catenin degradation and increases the nuclear translocation of β-catenin by direct phosphorylation at Ser675 and perhaps Ser552. 46, 47, 61, 62 Strikingly, we only detected changes in the phosphorylation of Ser675 (a PKA site), but not that of Ser33/Ser37 (glycogen synthase kinase-3β sites) in β-catenin in EP3 −/− ECs. Importantly, inhibition of PKA activity abolished the increase in Ser675 phosphorylation in β-catenin, blocked the nuclear translocation of β-catenin, attenuated the increase in Dll4 expression in EP3 −/− ECs, and subsequently rescued defective angiogenesis in vivo. Indeed, PKA plays an antiangiogenic role in angiogenesis. 63, 64 In summary, we demonstrated that the PGE 2 /EP3 axis promoted sprouting angiogenesis by suppression of PKA/β-catenin/Notch signaling. These data suggested that the EP3 receptor or downstream signaling pathways may serve as valuable targets for the treatment of vascular diseases.
